SCYNEXIS strengthened its financial position in Q4 2025 by receiving $24.8 million from GSK, extending its cash runway into 2028. While the company focused on advancing its second-generation fungerp SCY-247, total cash reserves decreased year-over-year to $56.3 million.

Scynexis, Inc. reported a net loss of $5.391 million for the first quarter of 2025, a substantial decrease from a net income of $0.411 million in the same period last year. Revenue significantly declined to $0.257 million from $1.373 million, primarily due to lower license agreement revenue. The company's cash and cash equivalents and investments totaled $53.8 million as of March 31, 2025.

SCYNEXIS reported a net loss of $21.3 million for the full year ended December 31, 2024, with total revenue of $3.7 million, a significant decrease from $140.1 million in 2023. The company ended 2024 with $75.1 million in cash, cash equivalents, and investments, projecting a cash runway into Q3 2026.

SCYNEXIS reported a net income of $67.0 million for the full year 2023, a significant turnaround from the previous year's net loss of $62.8 million. The company's cash, cash equivalents, and investments totaled $98.0 million at the end of 2023, providing a cash runway of more than two years. Key developments include the progression of SCY-247 and the exclusive license agreement with GSK for ibrexafungerp.

SCYNEXIS reported Q3 2022 financial results, with a focus on refocusing resources on the clinical development of ibrexafungerp for severe, hospital-based indications. BREXAFEMME net revenues were $1.6 million in Q3 2022, representing a 13% increase over Q2 2022. The company ended the quarter with $96.1 million in cash, cash equivalents, and short-term investments, projecting a cash runway into Q2 2024.

SCYNEXIS reported an increase in BREXAFEMME net product revenues from Q1 2022 to Q2 2022. The company has a projected cash runway into Q1 2024.

SCYNEXIS reported Q1 2022 financial results with BREXAFEMME generating $0.7 million in net product revenue. The company's cash balance was $95.2 million as of March 31, 2022, and with a recent public offering, SCYNEXIS expects to fund operations into Q1 2024. Clinical updates included positive results from the FURI and CARES trials and the Phase 3 CANDLE study.

SCYNEXIS reported fourth-quarter results with BREXAFEMME generating net product revenue of $0.6 million. The company highlighted the approval and launch of BREXAFEMME and advancements in ibrexafungerp's development across multiple indications.

SCYNEXIS reported BREXAFEMME net sales of $0.5 million since August. The company's cash balance was $100 million at the end of September, providing a cash runway into 2023. A Phase 1 trial of IV ibrexafungerp was completed.